Latest & greatest articles for prostate cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer screening

1. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm (...) with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could

2019 EvidenceUpdates

2. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. (PubMed)

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer.Systematic review and meta-analysis.Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018.Randomised controlled trials (...) mortality (IRR 0.99, 95% CI 0.98 to 1.01; moderate certainty) and may have no effect on prostate-specific mortality (IRR 0.96, 0.85 to 1.08; low certainty). Sensitivity analysis of studies at lower risk of bias (n=1) also demonstrates that screening seems to have no effect on all-cause mortality (IRR 1.0, 0.98 to 1.02; moderate certainty) but may have a small effect on prostate-specific mortality (IRR 0.79, 0.69 to 0.91; moderate certainty). This corresponds to one less death from prostate cancer per

Full Text available with Trip Pro

2018 BMJ

3. Prostate cancer screening

Prostate cancer screening Top results for prostate cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search (...) might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostate cancer screening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance

2018 Trip Latest and Greatest

4. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. (PubMed)

Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 13%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer (...) have an increased risk of prostate cancer compared with other men.To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostate cancer and subsequent treatment of screen-detected prostate cancer. The USPSTF also commissioned a review of existing decision analysis models and the overdiagnosis rate of PSA-based screening

Full Text available with Trip Pro

2018 JAMA

5. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Prostate cancer is the second leading cause of cancer death among US men.To systematically review evidence on prostate-specific antigen (PSA)-based prostate cancer screening, treatments for localized prostate cancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force.Searches of PubMed, EMBASE, Web of Science, and Cochrane (...) investigators independently rated study quality.Prostate cancer and all-cause mortality; false-positive screening results, biopsy complications, overdiagnosis; adverse effects of active treatments. Random-effects meta-analyses were conducted for treatment harms.Sixty-three studies in 104 publications were included (N = 1 904 950). Randomization to PSA screening was not associated with reduced risk of prostate cancer mortality in either a US trial with substantial control group contamination (n = 76 683

Full Text available with Trip Pro

2018 JAMA

6. Prostate Cancer: Screening

Prostate Cancer: Screening Final Update Summary: Prostate Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Is Prostate Cancer Screening Right For You? (794 KB, ) Prostate Cancer: Screening Release Date: May 2018 Recommendation Summary Population Recommendation Grade Men aged 55 to 69 years For men aged 55 to 69 years, the decision to undergo periodic prostate-specific (...) antigen (PSA)–based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Screening offers a small potential benefit of reducing the chance of death from prostate cancer in some men. However, many men will experience potential harms of screening, including false-positive results

2018 U.S. Preventive Services Task Force

7. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. (PubMed)

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment.To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality.The Cluster Randomized Trial of PSA Testing (...) stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostate cancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSA screening clinic.Among 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included in the analysis (n = 408 825; 98%). In the intervention group, 75 707 (40%) attended the PSA testing clinic and 67 313

Full Text available with Trip Pro

2018 JAMA

8. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. (PubMed)

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age (...) at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction

Full Text available with Trip Pro

2018 BMJ

9. Screening for Prostate Cancer*

Screening for Prostate Cancer* Screening for Prostate Cancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for Prostate Cancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr

2018 National Guideline Clearinghouse (partial archive)

10. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. (PubMed)

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. The ERSPC (European Randomized Study of Screening for Prostate Cancer) found that screening reduced prostate cancer mortality, but the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found no reduction.To evaluate whether effects of screening on prostate cancer mortality relative to no screening differed between the ERSPC and PLCO.Cox regression of prostate cancer death in each (...) trial group, adjusted for age and trial. Extended analyses accounted for increased incidence due to screening and diagnostic work-up in each group via mean lead times (MLTs), which were estimated empirically and using analytic or microsimulation models.Randomized controlled trials in Europe and the United States.Men aged 55 to 69 (ERSPC) or 55 to 74 (PLCO) years at randomization.Prostate cancer screening.Prostate cancer incidence and survival from randomization; prostate cancer incidence

Full Text available with Trip Pro

2017 Annals of Internal Medicine

12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa).The working panel performed a literature review of the new data (...) guidelines endorsed by the European Society for Radiotherapy and Oncology and the International Society of Geriatric Oncology and reflect the multidisciplinary nature of PCa management. A full version is available from the EAU office and online (http://uroweb.org/guideline/prostate-cancer/).The 2016 EAU-STRO-IOG Prostate Cancer (PCa) Guidelines present updated information on the diagnosis, and treatment of clinically localised prostate cancer. In Northern and Western Europe, the number of men diagnosed

Full Text available with Trip Pro

2016 EvidenceUpdates

13. Psychological Predictors of Prostate Cancer Screening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy (PubMed)

Psychological Predictors of Prostate Cancer Screening Behaviors Among Men Over 50 Years of Age in Hamadan: Perceived Threat and Efficacy Prostate cancer is the fourth most common cancer worldwide and is the second most lethal cancer.The aim of this study was to investigate psychological predictors of prostate cancer screening behaviors among men over 50 years of age in Hamadan.This cross-sectional study was carried out on 200 men over 50 years of age in Hamadan, west of Iran. Participants were (...) recruited with a cluster sampling method. The subjects completed a self-administered questionnaire including demographic characteristics, prostate cancer screening behaviors and psychological factors related to prostate cancer. Data was analyzed by SPSS-18 using chi-square, fisher exact test, and logestic regression.According to the results, 8.5 and 7.5 percent of participants reported history of digital rectal exam and prostate-specific antigen test, respectively. Also, the subjects reported 18.5

Full Text available with Trip Pro

2016 Iranian journal of cancer prevention

14. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. (PubMed)

Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. Prostate cancer incidence in men 75 years and older substantially decreased following the 2008 US Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this age group. It is unknown whether incidence has changed since the USPSTF recommendation against screening for all men in May 2012.To examine recent changes in stage-specific prostate (...) cancer incidence and PSA screening rates following the 2008 and 2012 USPSTF recommendations.Ecologic study of age-standardized prostate cancer incidence (newly diagnosed cases/100,000 men aged ≥50 years) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries and PSA screening rate in the past year among men 50 years and older without a history of prostate cancer who responded to the 2005 (n = 4580), 2008 (n = 3476), 2010 (n

Full Text available with Trip Pro

2015 JAMA

15. Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an economic analysis

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis Tawfik A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Tawfik A. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(11). 2015 Authors' conclusions PSA screening is associated with significant costs to the health care system when the cost of the PSA test itself is considered in addition to the costs of diagnosis, staging, and treatment of screen-detected PCs. Final publication URL Indexing Status

2015 Health Technology Assessment (HTA) Database.

16. Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs

2015 Health Technology Assessment (HTA) Database.

17. Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review

Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review Fergenbaum J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fergenbaum J. Harms (...) of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions Based on the evidence, the following conclusions can be made: There are major harms (unnecessary risks) associated with PSA screening, including: • harms associated with prostate biopsy • overdiagnosis There are minor harms associated with PSA screening including: • harms associated with PSA testing PSA-based screening for prostate cancer results

2015 Health Technology Assessment (HTA) Database.

18. Factors associated with prostate cancer screening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model (PubMed)

Factors associated with prostate cancer screening behavior among men over 50 in Fasa, Iran, based on the PRECEDE model Prostate cancer is one of the most common and lethal cancers in the world. The incidence of prostate cancer has been increasing in recent years. The purpose of this study was to investigate factors associated with prostate cancer screening behaviors among men over 50 in Fasa, Iran, based on the PRECEDE model.In this cross-sectional study, 400 men over 50 were studied in Fasa (...) , Iran. Data were collected via a questionnaire on demographic characteristics, such as age, number of children, occupation, education, marital status, smoking, and prostate cancer screening behaviors. Data were analyzed using SPSS software, version 16. Independent samples t-test and the Pearson Product Moment correlation coefficient were used for the statistical analyses.Men in the study had little knowledge (34.11±8.22) and attitude (28.23±7.23) about prostate cancer and screening behavior

Full Text available with Trip Pro

2015 Electronic physician

19. Prostate-Specific Antigen?Based Population Screening for Prostate Cancer

Prostate-Specific Antigen?Based Population Screening for Prostate Cancer PSA-Based Population Screening for Prostate Cancer: OHTAC Recommendation. May 2015; pp. 1–5 Prostate-Specific Antigen (PSA)–Based Population Screening for Prostate Cancer: OHTAC Recommendation HEALTH QUALITY ONTARIO ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATION OHTAC recommends against the introduction of a formal, population-based PSA screening program for prostate cancer in Ontario. BACKGROUND Prostate (...) Population Screening for Prostate Cancer: OHTAC Recommendation. May 2015; pp. 1–5 2 average-risk males reduces prostate cancer mortality or overall mortality, increases the detection of prostate cancer, or decreases the rate of aggressive or metastatic cancers? A systematic search of trials published between 2008 and 2013, specifically systematic reviews and randomized controlled trials (RCT) of PSA-based population screening programs, identified 11 reports, including 5 systematic reviews and 6 RCTs

2015 Health Quality Ontario

20. Randomised controlled trial: Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening

Randomised controlled trial: Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) be due to screening Article Text Therapeutics/Prevention Randomised controlled trial Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening Dragan Ilic 1 , Philipp Dahm 2 Statistics from Altmetric.com Commentary on : Schröder F , Hugosson J , Roobol M , et al . ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

2015 Evidence-Based Medicine (Requires free registration)